Skip to main content
Premium Trial:

Request an Annual Quote

Frost & Sullivan, ViaLogy, Matritech, Fluidigm, Xoma, Diversa, Ciphergen

Premium

Proteome Informatics Market Expected to Reach $358M by 2008, F&S Report Says

According to a new report by Frost & Sullivan, entitled “World Proteome Informatics Markets,” the market for proteomics-specific informatics totaled $128 million in 2002 and might reach $358 million by 2008. Standardization and the integration of interfaces are likely to be major areas of innovation, according to the report. While 2D gel electrophoresis and mass spectrometry have been successfully automated, the analysis software has not been able to keep pace. Furthermore, protein structures created by computational methods are prone to be inaccurate, leading to error-prone protein interaction databases, according to the company.


ViaLogy Receives Further Patent for QRI Technology

ViaLogy of Pasadena, Calif., has received another patent for its Quantum Resonance Interferometry technology for the detection and quantitation of biomolecular events, the company said this week. The patent, US Patent No. 6,671,625, extends QRI to protein arrays and broadens its applications to proteomics, pathway optimization, high-throughput screening, cellular assays, and time-based dosing studies by gene expression. It complements the company’s other three US patents, which describe the application of QRI technology to the analysis and interpretation of hybridized biochip and DNA microarray patterns, including diagnostic applications.


Matritech Now Traded on American Stock Exchange

Matritech of Newton, Mass., has started trading its common stock on the American Stock Exchange this week under the new ticker symbol MZT. Previously, the company’s stock was traded on the Nasdaq. Matritech uses proteomics technology to develop diagnostics for the detection of a variety of cancers.


Fluidigm Raises $21M in Private Financing Round

Fluidigm has raised $21 million in a private financing round led by EDB Investments, the investment arm of the Singapore Economic Development Board, and New-York-based Invus, the company said this week. Fluidigm said that the funds will be used to expand international sales, marketing, and support efforts for its Topaz integrated fluidic circuit technology for protein crystallization.


Xoma and Diversa Sign Antibody License and Development Agreement

Xoma of Berkeley, Calif., and Diversa of San Diego have signed a licensing and development agreement, the companies said this week. Diversa will license Xoma’s antibody expression technology as well as obtain an option for an antibody production license. In return, Xoma will receive a license fee and potential future milestone and royalty payments. Xoma and Diversa also plan to co-develop antibodies for autoimmune-related diseases. Xoma will provide Diversa with research funding, and Diversa will be entitled to milestone and royalty payments on any drugs developed under the agreement.


Ciphergen Receives Patent for Pattern Recognition Algorithm and Methods

Ciphergen Biosystems announced this week that it has received a patent, US Patent No. 6,675,104, covering software and methods that use a pattern recognition algorithm called classification and regression tree analysis to identify biomarker patterns from mass spectra.

“Together with SELDI-MS, this method forms a powerful ‘diagnostic pattern discovery technology’ which enables rapid discovery of patterns of discreet, identifiable protein biomarkers in human fluids and tissues that distinguish disease states from healthy ones,” Bill Rich, CEO of Ciphergen, said in a statement.